This is a story that keeps on running with several unexpected twists since we first wrote about Rina-S and ProfoundBio at #SITC23. Here's the latest update focused on implications associated with AbbVie's threat: bit.ly/4kXtYm0

The second first author pub from my PhD is now out in Nature Communications! 🪩 rdcu.be/dLqdZ Excited to share more 🧩 to the puzzle of how CD8 T cells “make their own off switch” from my pres in last year’s Society for Immunotherapy of Cancer #SITC23 Presidential Session. 🧵summarizing our work ⬇️

Delighted to see Genmab have snapped up ProfoundBio, an innovative up and coming ADC company. We covered their secret sauce in a C-suite interview at #SITC23 – it's not what you think it is: biotechstrategyblog.com/2023/11/unexpe…

1. Rina-S has been clinically beneficial even in patients with low FRa expression, as observed at #SITC23. Notably, the treatment discontinuation rate significantly reduced, suggesting a decrease in considerable side effects. This profile may contribute to the durability of

3/7 $MDNAF's MDNA113 new poster at #SITC23 T-MASK platform integrates ‘tumor targeting’ with ‘conditional activation’ to maximize anti-tumor efficacy and minimize systemic toxicity MDNA113 (T-MASK of anti-PD1-IL-2Sup) shows reduced IL-2R agonism with no change to PD1/PDL-1

I had the pleasure of meeting the first author Dorota Klysz at the #SITC23 speed mentoring session last November!

Although camidanlumab tesirine plus pembrolizumab produced encouraging responses in select pretreated patients with advanced solid tumors, the combination was associated with an increase in immune-related adverse effects. Society for Immunotherapy of Cancer #SITC23 onclive.com/view/camidanlu…

Treatment with camidanlumab tesirine was deemed well tolerated as a monotherapy and produced encouraging responses alongside pembrolizumab in select pretreated patients with advanced solid tumors. Society for Immunotherapy of Cancer #SITC23 onclive.com/view/camidanlu…

Camidanlumab Tesirine Plus Pembrolizumab Produces Responses But Increases Immune Toxicities in Select Solid Tumors Society for Immunotherapy of Cancer #SITC23 onclive.com/view/camidanlu…

#ICYMI: Last month, exciting findings from an National Cancer Institute-led study presented at #SITC23 reveal the potential of our Memory Cytokine-Enriched NK Cells (M-ceNK) in Small Cell Lung Cancer & neuroendocrine tumors. 🦠🔬 Read more: bit.ly/40pQ7Q7 #CancerResearch $IBRX

In the BASECAMP-1 trial, investigators continue to identify patients with advanced solid tumors who may be suitable to receive CAR T-Cell therapy, A2B530. Our Dr. Diane Simeone (Diane M. Simeone, MD) discusses the latest data from #SITC23 with OncLive.com: bit.ly/4a0968l

#ICYMI Last month, we attended Society for Immunotherapy of Cancer’s 38th Annual Meeting, where our R&D team presented two posters exploring our TriTCE platforms for the treatment of solid tumors. Learn about our research shared during #SITC23: zymeworks.com/zymeworks-pres…

🎉 Congratulations to Robert Schreiber, Ph.D., from Test Account, for being awarded the prestigious Smalley Memorial Award at #SITC23. We applaud his exceptional work and dedication to improving the #cancerimmunotherapy field. bit.ly/3QY3imZ Society for Immunotherapy of Cancer

📃This brief data walkthrough investigates the relationship of NLR with inflammation-immune mediators in #melanoma patients treated with #immunotherapy. Learn more about the rapid insights enabled with direct digital detection youtu.be/s2qE3NaALYA. #GeneExpression #SITC23

If you missed our collaborative poster on RNA-protein co-detection & analysis with Advanced Cell Diag. at #SITC23 click the link to view online now! cdn.indicalab.com/wp-content/upl… #pathtwitter #digitalpathology #spatialbiology #AdvancingYourRNAISH #HALOai #AdvancedCellDiagnostics #IndicaLabs

At #SITC23, our Spatial Biology Manager, Danielle Fails, presented a poster profiling cytokeratins in the human tumor microenvironment, using data generated in-house using Bethyl Laboratories antibodies. Her poster is now available to view on our website: fortislife.com/products/poste…

Check out our Oncology-focused nCounter direct digital detection gene expression panels optimized for biomarker development, cell therapy manufacturing, pre-clinical research, clinical trial monitoring... and so much more! bit.ly/3SZGZA0. #Immunotherapy #SITC23